{"id":"NCT00818519","sponsor":"Bayer","briefTitle":"GA YAZ ACNE in China Phase III","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of an Oral Contraceptive Preparation YAZ (Drospirenone 3 mg / Ethinylestradiol 20 µg) for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2009-01-07","resultsPosted":"2011-06-09","lastUpdate":"2015-08-25"},"enrollment":179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"EE20/Drospirenone (YAZ, BAY86-5300)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"EE20/Drospirenone (YAZ, BAY86-5300)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.","primaryOutcome":{"measure":"Percent Change From Cycle 6 to Baseline in the Total Lesion Count (Open and Closed Comedones, Papules, Pustules, and Nodules) in the FAS (Full Analysis Set)","timeFrame":"Cycle 6 (Day 15±3 days of Treatment Cycle 6) and Baseline","effectByArm":[{"arm":"EE20/Drospirenone (YAZ, BAY86-5300)","deltaMin":66.79,"sd":31.45},{"arm":"Placebo","deltaMin":37.71,"sd":118.73}],"pValues":[]},"eligibility":{"minAge":"14 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":7,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Menorrhagia","Metrorrhagia","Nasopharyngitis","Blood cholesterol increased","Breast mass"]}}